ARCT
Arcturus Therapeutics Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.82
+1.67%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.4x
Market Cap
$449.65M
MomentumView details →
1D Return
+1.67%
YTD Return
+159.38%
RSI (14)
73.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.4x
Market Cap
$449.65M
RSI (14)
73.1
MomentumView details →
1D Return
+1.67%
YTD Return
+159.38%
SummaryUpdated Jun 1, 2026
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a biotechnology company founded in 2013 and headquartered in San Diego, California. The company specializes in developing RNA-based medicines, focusing on vaccines for infectious diseases and therapeutic treatments for rare genetic disorders affecting the liver and respiratory system. Since going public in 2013, Arcturus has evolved from an early-stage biotech into a clinical-stage company with multiple programs in human trials and its first approved product - a COVID-19 vaccine launched in Japan.
Similar companies
Latest newsMore news →
Arcturus Therapeutics Holdings Inc. held its Q2 2026 earnings call on August 7, 2026.28d agoArcturus Therapeutics reported a second-quarter loss of $0.84 per share, beating the Zacks Consensus Estimate of a loss of $1.07, and compared to a loss of $0.34 per share a year ago.29d agoArcturus Therapeutics regained global rights to its KOSTAIVE COVID-19 vaccine and self-amplifying mRNA platform after ending its collaboration with CSL Seqirus.29d ago